

FHIT Antibody

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP51208

Product Information

Application WB, ICC, IHC-P

Primary Accession
Reactivity
Human
Host
Rabbit
Clonality
Polyclonal
Calculated MW
16858

Additional Information

Gene ID 2272

Other Names Bis(5'-adenosyl)-triphosphatase, AP3A hydrolase, AP3Aase, Diadenosine 5',

5'''-P1, P3-triphosphate hydrolase, Dinucleosidetriphosphatase, Fragile

histidine triad protein, FHIT

Dilution WB~~1:1000 ICC~~N/A IHC-P~~N/A

Format 0.01M PBS, pH 7.2, 0.09% (W/V) Sodium azide, Glycerol 50%

Storage Store at -20 °C.Stable for 12 months from date of receipt

Protein Information

Name FHIT

Function Possesses dinucleoside triphosphate hydrolase activity (PubMed: 12574506,

PubMed:<u>15182206</u>, PubMed:<u>8794732</u>, PubMed:<u>9323207</u>, PubMed:<u>9543008</u>, PubMed:<u>9576908</u>). Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP (PubMed:<u>12574506</u>, PubMed:<u>15182206</u>, PubMed:<u>8794732</u>, PubMed:<u>9323207</u>, PubMed:<u>9543008</u>, PubMed:<u>9576908</u>). Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP (PubMed:<u>8794732</u>). Exhibits adenylylsulfatase activity, hydrolyzing adenosine 5'-phosphosulfate to yield AMP and sulfate

(PubMed: 18694747). Exhibits adenosine 5'-monophosphoramidase activity, hydrolyzing purine nucleotide phosphoramidates with a single phosphate group such as adenosine 5'monophosphoramidate (AMP-NH2) to yield AMP

and NH2 (PubMed: 18694747). Exhibits adenylylsulfate-ammonia adenylyltransferase, catalyzing the ammonolysis of adenosine 5'-

phosphosulfate resulting in the formation of adenosine 5'- phosphoramidate

(PubMed:<u>26181368</u>). Also catalyzes the ammonolysis of adenosine

5-phosphorofluoridate and diadenosine triphosphate (PubMed:<u>26181368</u>). Modulates transcriptional activation by CTNNB1 and thereby contributes to

regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5 (PubMed:18077326). Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways (PubMed:16407838). Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis (PubMed:15313915). Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake (PubMed:12574506, PubMed:19622739). Functions as a tumor suppressor (By similarity).

Cellular Location Cytoplasm. Mitochondrion. Nucleus

Tissue Location Low levels expressed in all tissues tested. Phospho-FHIT observed in liver and

kidney, but not in brain and lung Phospho-FHIT undetected in all tested

human tumor cell lines

Background

Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP. Can also hydrolyze P(1)-P(4)-bis(5'- adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP. Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5. Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways. Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis. Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity. Functions as tumor suppressor.

References

Ohta M.,et al.Cell 84:587-597(1996).
Druck T.,et al.Cancer Res. 57:504-512(1997).
Naqvi R.A.,et al.Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
Barnes L.D.,et al.Biochemistry 35:11529-11535(1996).
Gemmill R.M.,et al.Proc. Natl. Acad. Sci. U.S.A. 95:9572-9577(1998).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.